USPTO Examiner PIHONAK SARAH - Art Unit 1627

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18947694Liquid Tasimelteon Formulations and Methods of Use ThereofNovember 2024May 2025Allow610NoNo
18932033HYDROCORTISONE ORAL LIQUID FORMULATIONSOctober 2024June 2025Allow720YesNo
18665714LIQUID ORAL FORMULATIONS FOR TADALAFILMay 2024November 2024Allow610NoNo
18626876LIQUID ORAL FORMULATIONS FOR SILDENAFILApril 2024November 2024Allow710YesNo
18604704ISATIN DERIVATIVESMarch 2024April 2025Allow1410NoNo
18582125METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESSFebruary 2024November 2024Abandon910NoNo
18443889HYDROCORTISONE ORAL LIQUID FORMULATIONSFebruary 2024September 2024Allow710NoNo
18577088A System and Method for Measuring and Stimulating AutophagyJanuary 2024June 2025Abandon1711NoNo
18403049O-{1-[(3,5-DINITROBENZOYL)AMINO]PROPAN-2-YL} (4-CHLOROPHENYL)CARBAMOTHIOATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)January 2024April 2024Allow310NoNo
18391243DRUG DELIVERY FORMULATIONSDecember 2023September 2024Allow920NoNo
18534234METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESSDecember 2023January 2025Abandon1420NoNo
18387170COMBINATION THERAPIESNovember 2023December 2024Abandon1311NoNo
183797532-(BENZO[D]OXAZOL-2-YL)-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2- YLTHIO)ACETOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow510NoNo
18552908USE OF CHOLECALCIFEROL AS ADJUVANT IN THE TREATMENT OF MUSCULAR DYSTROPHIESSeptember 2023May 2024Allow710NoNo
18368497SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEINSeptember 2023May 2025Allow2020NoNo
18241881SYNERGISTIC COMBINATIONS OF ATORVASTATIN AND CANNABIDIOL (CBD)September 2023June 2024Allow910NoNo
18365266LIQUID ORAL FORMULATIONS FOR SILDENAFILAugust 2023February 2024Allow610NoNo
18227168PRODUCTS AND METHODS FOR MICROBE INHIBITION ON LIVE PLANTS BY CARBOXYLIC ACIDS AND THEIR SALTSJuly 2023April 2025Allow2110NoNo
18224898Compositions and Methods for Treating Defects in Avascular Cartilaginous Tissue by Directly Administering One or More Metabolites of SimvastatinJuly 2023March 2025Allow2010YesNo
18342387METHODS FOR TREATING HEART FAILURE BY ADMINISTERING CARDIAC SARCOMERE ACTIVATORSJune 2023January 2024Allow710YesNo
18333532Compounds and Methods for Treating or Preventing Anterior Segment Ocular Disorders and/or Retinal DegenerationsJune 2023April 2025Allow2220NoNo
18199812CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUNDMay 2023November 2023Allow610NoNo
18316841METHODS AND COMPOSITIONS FOR TREATING EXCESSIVE SLEEPINESSMay 2023November 2023Allow610NoNo
18195245METHODS FOR ACUTE AND LONG-TERM TREATMENT OF ALCOHOL DEPENDENCE USING IBOGAINE AND DERIVATIVES THEREOFMay 2023April 2025Abandon2410NoNo
18308723LIQUID ORAL FORMULATIONS FOR TADALAFILApril 2023January 2024Allow820YesNo
18298175VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOFApril 2023November 2023Allow710YesNo
18130059N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAYApril 2023September 2024Allow1710NoNo
18187385CREATINE, ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE THEREOFMarch 2023September 2023Allow610NoNo
18113458HYDROCORTISONE ORAL LIQUID FORMULATIONSFebruary 2023November 2023Allow921YesNo
18165908METHODS FOR TREATING CARDIOVASCULAR DISEASESFebruary 2023February 2025Allow2420YesNo
18100426SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USEJanuary 2023April 2025Allow2711NoNo
18100039INTRATHECAL ADMINISTRATION OF LEVETIRACETAMJanuary 2023November 2024Abandon2210NoNo
18148659VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOFDecember 2022August 2023Allow820NoNo
18089920COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISORDERSDecember 2022January 2025Allow2521NoNo
18071344Treatment of Autism Spectrum Disorders with Ergothioneine, Selenoneine, or Combinations ThereofNovember 2022April 2024Allow1730YesNo
18058064COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSESNovember 2022April 2025Allow2811NoNo
17989174CARBAMOYL CYCLOHEXANE DERIVATIVES FOR TREATING AUTISM SPECTRUM DISORDERNovember 2022March 2025Abandon2701NoNo
17986934PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANTNovember 2022September 2024Allow2210NoNo
17981220COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASESNovember 2022June 2024Abandon1901NoNo
17968232COMPOUNDS AND METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH EXTRA-INTESTINAL MANIFESTATIONSOctober 2022May 2024Allow1910NoNo
18046876NOVEL TREATMENT FOR HOT FLUSHESOctober 2022November 2024Allow2520NoNo
17960343Ephedrine Compositions and MethodsOctober 2022May 2024Allow1910NoNo
17954421PHARMACEUTICAL FORMULATION OF PALBOCICLIB AND A PREPARATION METHOD THEREOFSeptember 2022April 2025Abandon3010NoNo
17947509NEURONAL MODULATIONSeptember 2022September 2024Allow2410NoNo
17946585Methods for Treating Immune Thrombocytopenia by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy- Phenyl) Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-EnenitrileSeptember 2022August 2024Allow2320NoNo
17943986METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASESeptember 2022February 2025Allow2921NoNo
17942486THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR CONTROLLED DRUG DELIVERYSeptember 2022March 2025Allow3021NoNo
17930824Varenicline Compound and Process of Manufacture ThereofSeptember 2022June 2023Allow920YesNo
17941627SLEEP IMPROVING AGENTSeptember 2022August 2024Allow2320YesNo
17930538THIENOPYRROLE COMPOUNDSSeptember 2022April 2024Allow1911NoNo
17930570ANHYDROUS COMPOSITIONS OF EGFR INHIBITORS AND METHODS OF USESeptember 2022June 2024Abandon2211NoNo
17823546LIQUID ORAL FORMULATIONS FOR SILDENAFILAugust 2022May 2023Allow811NoNo
17897944FORMULATIONS FOR DELIVERY TO THE EARAugust 2022May 2025Abandon3321YesNo
17821869CREATINE, ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE THEREOFAugust 2022February 2023Allow621YesNo
17893905TREATMENT OF CNS CONDITIONSAugust 2022October 2024Abandon2610NoNo
17821146SMALL MOLECULE BCL-2 FUNCTIONAL CONVERTERS AS CANCER THERAPEUTICSAugust 2022March 2025Allow3131YesNo
17891662RESVERATROL PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOFAugust 2022August 2024Abandon2411NoNo
17877339CISPLATIN ANALOGUE WITH POTENT ANTI-CANCER EFFECTS AND SYNTHESIS THEREOFJuly 2022August 2024Allow2521NoNo
17873453COMPOSITIONS AND METHODS FOR THE TREATMENT OF BRONCHOPULMONARY DYSPLASIA (BPD) AND BPD-ASSOCIATED PULMONARY HYPERTENSIONJuly 2022April 2025Allow3341NoNo
17813760EYE WASH COMPOSITIONS AND METHODSJuly 2022February 2024Allow1921NoNo
17867279METHOD OF TREATING CNS DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDSJuly 2022October 2024Abandon2711NoNo
17841567CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUNDJune 2022April 2023Allow1020NoNo
17805875SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORSJune 2022January 2024Allow1910NoNo
17833789FORMULATION OF (E)-2,4,6-TRIMETHOXYSTYRYL-3-[(CARBOXYMETHYL)AMINO]-4-METHOXYBENZYLSULPHONE WITH ENHANCED STABILITY AND BIOAVAILABILITYJune 2022July 2024Allow2620NoNo
17832921LIQUID ORAL FORMULATIONS FOR TADALAFILJune 2022January 2023Allow820NoNo
17828681AGENT FOR TREATING NOCTURNAL POLLAKIURIAMay 2022January 2025Allow3130YesNo
17750354FORMULATIONS COMPRISING TRIPTAN COMPOUNDSMay 2022June 2024Allow2520NoNo
17746801COVALENT INHIBITORS OF KRASMay 2022October 2024Abandon2911NoNo
17741009PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORSMay 2022November 2023Allow1920YesNo
17740148SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEINMay 2022June 2023Allow1350YesNo
17738022USE OF COENZYME FACTOR FOR ACTIVATION OF ATP PRODUCTION IN CELLMay 2022July 2023Allow1500NoNo
17738027USE OF COENZYME FACTOR FOR ACTIVATION OF ATP PRODUCTION IN CELLMay 2022July 2023Allow1400NoNo
177733748-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOFApril 2022June 2025Allow3810NoNo
17731831USE OF TRADIPITANT IN MOTION SICKNESSApril 2022August 2024Abandon2710NoNo
17725234PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USE THEREOFApril 2022March 2024Allow2311NoNo
17721857VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOFApril 2022January 2023Allow1021YesNo
17716657HETEROCYCLIC COMPOUNDS AND USES THEREOFApril 2022February 2024Abandon2201NoNo
17711572Use of Thiol Compounds to Treat Neurological DiseaseApril 2022June 2024Allow2611NoNo
17656743METHODS FOR TREATING PULMONARY FIBROSISMarch 2022June 2024Allow2720YesNo
17655813CREATINE, ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE THEREOFMarch 2022March 2023Abandon1211NoNo
17642410DRUG DELIVERY FORMULATIONSMarch 2022April 2025Allow3720YesNo
17688608EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONSMarch 2022November 2023Abandon2141NoNo
17681132FORMULATIONS OF TEGAVIVINT AND RELATED COMPOUNDSFebruary 2022July 2024Allow2911YesNo
17652427CALCIUM LACTATE COMPOSITIONS AND METHODS OF USEFebruary 2022March 2024Allow2520NoNo
17679842PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHYFebruary 2022May 2024Allow2711NoNo
17675540TUMESCENT INFILTRATION DRUG DELIVERY OF HIGH SUBCUTANEOUS DRUG CONCENTRATIONS WITH PROLONGED LOCAL AND SYSTEMIC EFFECTS AND MINIMAL LOCAL OR SYSTEMIC TOXICITYFebruary 2022March 2025Allow3761YesNo
17675506TUMESCENT INFILTRATION DRUG DELIVERY OF HIGH SUBCUTANEOUS DRUG CONCENTRATIONS WITH PROLONGED LOCAL AND SYSTEMIC EFFECTS AND MINIMAL LOCAL OR SYSTEMIC TOXICITYFebruary 2022March 2023Allow1321YesNo
17667285METHODS FOR TREATING TESTICULAR AND OVARIAN ADRENAL REST TUMORSFebruary 2022January 2025Abandon3521NoNo
17666216TUMESCENT INFILTRATION DRUG DELIVERY OF CANNABINOIDSFebruary 2022April 2025Allow3821YesNo
17591944Low-Dose Carbachol Compositions And Methods For Treatment Of Night Vision DisturbanceFebruary 2022August 2024Abandon3021NoNo
17577156Application of CaMK4 in Preparation of Medicine for Preventing and Treating psoriasisJanuary 2022May 2025Allow4020NoNo
17567653Compositions and Methods Using a Cannabinoid to Enhance Bioavailability of a StatinJanuary 2022June 2023Allow1741YesNo
17562973ANTIVIRAL TREATMENTDecember 2021April 2022Allow420YesNo
17559571METHODS FOR ADMINISTERING COMPOSITIONS COMPRISING HYDROXYTYROSOL AND BOSWELLIC ACIDDecember 2021January 2024Allow2410NoNo
17547118Prodrugs of Fumarates and Their Use in Treating Various DiseasesDecember 2021October 2023Allow2210NoNo
17643237CNS MODULATORSDecember 2021May 2024Abandon3011YesNo
17534837Methods For Ensuring Resuspension Of Paliperidone Palmitate FormulationsNovember 2021November 2022Allow1211YesNo
17528645COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING INFLAMMATORY OR IMMUNE-MEDIATED CONDITIONS OF SURFACE TISSUESNovember 2021October 2023Abandon2331NoYes
17595471ANTI-ADHESIVE HYDROGEL COMPOSITIONNovember 2021April 2025Allow4010NoNo
17527428PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSISNovember 2021February 2025Allow3930NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PIHONAK, SARAH.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
15
Examiner Affirmed
13
(86.7%)
Examiner Reversed
2
(13.3%)
Reversal Percentile
24.0%
Lower than average

What This Means

With a 13.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
91
Allowed After Appeal Filing
17
(18.7%)
Not Allowed After Appeal Filing
74
(81.3%)
Filing Benefit Percentile
20.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PIHONAK, SARAH - Prosecution Strategy Guide

Executive Summary

Examiner PIHONAK, SARAH works in Art Unit 1627 and has examined 1,578 patent applications in our dataset. With an allowance rate of 58.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 29 months.

Allowance Patterns

Examiner PIHONAK, SARAH's allowance rate of 58.5% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PIHONAK, SARAH receive 1.81 office actions before reaching final disposition. This places the examiner in the 55% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PIHONAK, SARAH is 29 months. This places the examiner in the 44% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +50.8% benefit to allowance rate for applications examined by PIHONAK, SARAH. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 56.8% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 42.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 37% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 77.3% of appeals filed. This is in the 65% percentile among all examiners. Of these withdrawals, 70.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 50.7% are granted (fully or in part). This grant rate is in the 62% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 2.9% of allowed cases (in the 82% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.1% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.